GKB Ophthalmics shareholders approved the re-appointment of K.G. Gupta as Chairman and Managing Director for a three-year term effective April 1, 2027. The decision was ratified at the company's 44th Annual General Meeting held on August 25, 2026, with all resolutions passing unanimously.

The Board cited Gupta's extensive experience in the ophthalmic lens industry and his role in ensuring operational sustainability during challenging times as key reasons for the continuity of his leadership. The resolution also served as specific shareholder approval under Section 196(3) of the Companies Act, 2013, given that Gupta has exceeded the age limit of 70 years.

Leadership Continuity and Governance

In addition to Gupta's re-appointment, shareholders approved the re-appointment of Cedric Lobo as Executive Whole Time Director for a two-year term from June 1, 2026, to May 31, 2028. Lobo manages human resources, legal compliance, and factory operations. His remuneration is set between ₹9.50 lakh and ₹15.00 lakh per annum, inclusive of perquisites and retiral benefits.

The meeting also addressed related party transactions and subsidiary management. Shareholders approved limits for transactions with GKB Vision Private Limited and Lensco - The Lens Company for FY27. Furthermore, approval was granted for the payment of monthly remuneration of $7,400 to Gaurav Gupta, CEO of Lensco, who is the son of K.G. Gupta.

Financial Context and Dividend Policy

The Chairman informed members that no dividend was declared for FY26 due to operating losses. The company reported an annual standalone turnover of ₹25.64 crore and net worth of ₹12.89 crore as per audited financial statements for FY26. These figures are below the thresholds required for certain corporate governance compliances under SEBI Listing Regulations, specifically Regulation 15(2), which exempts companies with paid-up equity capital below ₹10 crore and net worth below ₹25 crore for three consecutive years.

Voting Results Summary

All seven resolutions placed before the AGM were passed with 100% votes in favor. The voting results reflect strong shareholder support for the proposed leadership changes and transaction approvals.

What the Numbers Show

The disclosure reveals a significant concentration of governance and operational control within the promoter family. K.G. Gupta holds 9,02,812 equity shares directly, while Krishna Gopal Gupta & Sons (HUF) holds an additional 3,00,053 shares. This familial control extends to key subsidiaries, where Gaurav Gupta serves as CEO of Lensco, a step-down subsidiary. The approval of related party transaction limits totaling ₹42.00 crore (₹27.00 crore with GKB Vision and ₹15.00 crore with Lensco) highlights the operational dependency on these affiliated entities for buying and selling ophthalmic lenses and consumables.

Hexiris Ophthalmics will present first-in-human clinical results for its OBi glaucoma platform at five major ophthalmology meetings across Europe and North America this fall.

The physician-founded developer announced a program starting with the Ophthalmology Futures Forum in London on September 10, during the week of the 44th ESCRS Annual Congress. Co-founder Dr. Nir Shoham-Hazon will present the company’s clinical experience and platform details to an audience of innovators, clinicians, and investors.

Clinical Progress and Platform Design

The company’s OBi platform comprises four instruments: OBi Core, OBi Gon, OBi Shunt, and OBi Spacer. These devices are designed to span major aqueous outflow pathways, enabling glaucoma surgery to be performed at the slit lamp rather than in an operating room. This approach aims to address access bottlenecks, particularly given that a Rutgers University analysis presented at ARVO 2026 found approximately 80 percent of US counties have no glaucoma specialist.

In the first-in-human series for OBi Core, eleven eyes with mild, moderate, and advanced glaucoma were treated by three surgeons. The procedure is minimally invasive, ab externo, and transconjunctival, requiring no capital equipment. Early postoperative intraocular pressures ranged from the single digits to the low teens. No device- or procedure-related adverse events were observed during this series.

Meeting Schedule

Hexiris will participate in five key events over the coming weeks:

• Ophthalmology Futures Forum, London, September 10: Presentation of platform and first-in-human results.
• ESCRS Annual Congress, London, September 11 to 15: Presence at the 44th Congress of the European Society of Cataract and Refractive Surgeons.
• Canadian Glaucoma Society Meeting, Halifax, September 19 to 20: Hands-on OBi demonstrations for the Canadian glaucoma community.
• 57th Sally Letson Symposium, Ottawa, September 24 to 26: Hands-on OBi training for attending surgeons under the theme "Reimagining Glaucoma Care Together."
• AAO 2026, New Orleans, October 9 to 12: Showcase of the OBi platform and hands-on demonstrations at the American Academy of Ophthalmology Annual Meeting.

Commercial Outlook and Regulatory Status

These engagements precede the planned commercial introduction of OBi Core and OBi Gon in select markets in early 2027, subject to applicable regulatory requirements. Additional clinical series are being compiled, and the company’s first clinical studies are underway in Canada.

Regulatory status varies by product and jurisdiction. OBi Core holds a Health Canada medical device licence and is FDA registered. OBi Gon, OBi Shunt, and OBi Spacer are investigational and not approved for commercial use in the United States, Canada, or the European Union, except where specifically authorized.